WASHINGTON (Reuters)—U.S. President-elect Donald Trump aims to replace Obamacare with a plan that would envisage “insurance for everybody,” he said in an interview with the Washington Post published on Sunday night. Trump did not give the newspaper specifics about his proposals to replace Democratic President Barack Obama’s signature health insurance law, but said the plan…
The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

AMA Updates Code of Medical Ethics
Eight years ago, the American Medical Association’s (AMA) Council on Ethical and Judicial Affairs embarked on a comprehensive review of the AMA Code of Medical Ethics. What emerged after years of hard effort, intensive feedback and thoughtful revisions was a modernized version of the guide, which the AMA House of Delegates voted to adopt in…
Stronger Malpractice Laws May Not Prevent Surgical Complications
(Reuters Health)—More aggressive malpractice climates don’t necessarily protect patients from surgical complications, a new study suggests. Supporters of medical malpractice laws that make it easier for patients to sue doctors say these protections are necessary to improve care. But in the current study, the risk of litigation didn’t translate into better outcomes, said study leader…
U.S. Supreme Court to Hear Dispute Over Biologic Drug Sales
NEW YORK (Reuters)—The U.S. Supreme Court on Friday agreed to hear a dispute over whether companies that make copycat versions of biologic drugs must wait six months after winning federal approval to begin selling them. The justices will take up an appeal by Novartis AG of a 2015 federal appeals court decision that prevented the…
U.S. Senate to Act on Obamacare Repeal, McConnell Says
WASHINGTON (Reuters)—The U.S. Senate will take its first steps toward repealing President Barack Obama’s signature healthcare reform act by the end of the week, Senate Majority Leader Mitch McConnell (R-Ky.) said on Sunday. Speaking on CBS’s “Face the Nation,” McConnell said: “There ought not to be a great gap” between repealing the act and replacing…
Lesinurad with Allopurinol When Allopurinol Alone Is Insufficient
Current guidelines for the long-term management of gout recommend a combination of lifestyle management and/or pharmacotherapy to lower serum UA levels to <6.0 mg/dL in most patients or <5.0 mg/dL in patients with more severe disease. Allopurinol is the most widely used xanthine oxidase inhibitor and is recommended in treatment guidelines as a first-line urate-lowering…

CMS Cancels Medicare Part B Demonstration Project
When the controversial Medicare Part B Drug Payment Model final rule was not released by the Centers for Medicare & Medicaid Services (CMS) as expected before Nov. 21, it signaled an increasing likelihood of defeat for the proposed rule—a signal proved true on Dec. 15. A spokesperson for the CMS said, “After considering comments, CMS…
Advocating Where It Counts: A Conversation with Incoming Government Affairs Committee Chair Angus Worthing, MD, FACR, FACP
As he prepares to take on his newest volunteer role with the ACR, leading the Government Affairs Committee (GAC), Angus Worthing, MD, FACR, FACP, is looking forward to making the most of the opportunities that a unified government can offer the ACR in advocating for rheumatology care. “Advocacy is an investment in our profession—regardless of…

Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed
Nonsteroidal anti-inflammatory drugs (NSAIDs) have been used therapeutically since the 1960s.1 Evidence of adverse cardiovascular outcomes led to the withdrawal of the selective COX-2 inhibitor rofecoxib in September 2004, when the question of cardiovascular safety of NSAIDs first came into the limelight.2 Valdecoxib (Bextra) was subsequently withdrawn from the market in April 2005 due to…

Rheumatology Research Foundation Recognizes Donors of Merit
On Nov. 12, nearly 150 supporters of the Rheumatology Research Foundation gathered at the St. Regis Washington, D.C., for the Donors of Merit recognition dinner. This annual event honors those who contributed to the Foundation throughout the year. Foundation President Eric Matteson, MD, MPH, applauded leaders who have played an essential role in the Foundation’s success….
- « Previous Page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- …
- 250
- Next Page »
